Zobrazeno 1 - 10
of 2 609
pro vyhledávání: ''
Autor:
TAKEHIRO OTOSHI, TATSUYA NAGANO, JONGUK PARK, KOJI HOSOMI, TOMOYA YAMASHITA, MOTOKO TACHIHARA, TOKIKO TABATA, REINA SEKIYA, YUGO TANAKA, KAZUYUKI KOBAYASHI, KENJI MIZUGUCHI, TOMOO ITOH, YOSHIMASA MANIWA, JUN KUNISAWA, YOSHIHIRO NISHIMURA
Publikováno v:
Anticancer Research. 42:1589-1598
The gut microbiome plays an important role in the immune system and has attracted attention as a biomarker of several diseases, including cancer. In this study, we examined the relationship between the gut microbiome and lung cancer progression.Femal
Autor:
Kiki C. Andree, Menno Tamminga, Harry J.M. Groen, T. Jeroen N. Hiltermann, Ed Schuuring, Leon W.M.M. Terstappen, Anouk Mentink, Hilda van den Bos, Peter M. Lansdorp, Wim Timens, Diana C.J. Spierings
Publikováno v:
British journal of cancer, 126, 409-418. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
Br J Cancer
British Journal of Cancer, 126. Nature Publishing Group
BACKGROUND: Circulating tumour cells (CTCs) can be used to monitor cancer longitudinally, but their use in non-small cell lung cancer (NSCLC) is limited due to low numbers in the peripheral blood. Through diagnostic leukapheresis (DLA) CTCs can be ob
Publikováno v:
Future Oncology. 18:679-690
Objective: D-dimer is correlated to the poor prognosis of non-small-cell lung cancer. The study aimed to investigate the association between plasma D-dimer and concomitant mutations in non-small-cell lung cancer. Methods: A total of 517 non-small-cel
Autor:
Tomoko Yoshida, Kazuhiko Takeda, Toshihiko Kaneda, Hiroaki Yanagimoto, Takao Yoshida, Kayoko Kibata, Koji Tsuta, Takayasu Kurata, Hiroshige Yoshioka
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-10 (2022)
Background Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy
Autor:
Jitsuo Usuda, Susumu Takeuchi, Kengo Nagashima, Noriko Motoi, Masahiro Seike, Jun Matsubayashi, Hideaki Shiraishi, Kazufumi Honda, Shun-ichi Watanabe, Rintaro Noro, Kaoru Kubota, Xue Meng, Tatsuya Inoue, Huang Wilber, Ayumi Kashiro, Tetsuya Okano, Yukihiro Yoshida, Shinobu Kunugi, Akihiko Gemma, Norihiko Ikeda
Publikováno v:
Cancer Science. 113:1002-1009
Although adjuvant tegafur/uracil (UFT) is recommended for patients with completely resected stage I non-small cell lung cancer (NSCLC) in Japan, only one-third of cases has received adjuvant chemotherapy according to real-world data. Therefore, robus
Autor:
BADIU, DUMITRU CRISTINEL, ZGURA, ANCA, MEHEDINTU, CLAUDIA, HAINEALA, BOGDAN, ANGHEL, RODICA, BACINSCHI, XENIA
Publikováno v:
In Vivo
Background/Aim: Lung cancer is the most common cancer worldwide. Cancer immunotherapy is the activation of the immune system against cancer. The latest method of immunotherapy involves immune checkpoint inhibitors. Increased levels of programmed deat
Autor:
Shankha Satpathy, Fernanda Martins Rodrigues, Li Ding, Humam Kadara, Chandra Goparaju, Steven A. Carr, Irena Lanc, Jeffrey P. Ward, Ignacio I. Wistuba, Siddhartha Devarakonda, Ashiq Masood, Robert S. Fulton, Harvey I. Pass, Richard K. Wilson, Lucinda Fulton, Ramaswamy Govindan, Kymberlie H. Pepin, Daniel Morgensztern, Yize Li, Michael A. Gillette, Saiama N. Waqar, Sumithra Sankararaman
Publikováno v:
J Clin Oncol
PURPOSE Approximately 10%-40% of patients with lung cancer report no history of tobacco smoking (never-smokers). We analyzed whole-exome and RNA-sequencing data of 160 tumor and normal lung adenocarcinoma (LUAD) samples from never-smokers to identify
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 148:565-575
Purpose: NRAS plays a pivotal role in progression of various kinds of somatic malignancies; however, the correlation between NRAS and lung adenocarcinoma is less known. We aim to analyze the prognostic value of NRAS expression in lung adenocarcinoma,
Autor:
Gary Middleton, Alex G. Richter, Akshay J Patel, Ti-Myen Tan, Jonathan M. Blackburn, Babu Naidu
Publikováno v:
British Journal of Cancer
Background Lung cancer is the leading cause of cancer-related death worldwide. Surgical resection remains the definitive curative treatment for early-stage disease offering an overall 5-year survival rate of 62%. Despite careful case selection, a sig
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz